REG - Creo Medical Group - Creo and Intuitive amend collaboration agreement

Creo MedicalAnnouncement

02/07/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240702:nRSB6973Ua&default-theme=true

RNS Number : 6973U  Creo Medical Group PLC  02 July 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Creo and Intuitive amend collaboration agreement

 

Intuitive's Ion Endoluminal System and Creo's MicroBlate™ Flex ablation
device used in pioneering lung cancer treatment

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, provides an update in relation to the multi-year
collaboration agreement with Intuitive Surgical Inc. ("Intuitive"), which will
now expand the number of sites in the UK and Europe undertaking combined lung
cancer diagnostic and microwave ablation procedures.

 

Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive
care and the pioneer of robotic-assisted surgery. Under the collaboration
agreement, certain Creo products will be tested for compatibility with
Intuitive's Ion Endoluminal System, and it provides a framework for
undertaking joint clinical studies ahead of commercial launch of the
MicroBlate Flex device.

 

Accelerated timescale for further Lung Tissue ablation cases across UK and
Europe

As announced in May 2023, the first in-human use of the Company's MicroBlate
Flex device for the microwave ablation of soft tissue lung lesions was
successfully completed by Professor Shah at Royal Brompton Hospital, part of
Guy's and St Thomas' NHS Foundation Trust. The initial MicroBlate Flex
procedure was undertaken in a clinical study(1) which is ongoing. In March
2024, Professor Shah and his team announced that they had performed the first
ever robotic-guided microwave ablation of lung tissue in the same sitting as a
diagnostic procedure(2).

 

The collaboration agreement amendment will support the collection of
post-market clinical evidence as part of a controlled market release ahead of
the next stage in commercialisation of the MicroBlate Flex device. To achieve
this, Intuitive and Creo have agreed to extend the number of sites in the UK
and Europe undertaking robotic-guided microwave ablation procedures for lung
cancer.

 

Over the next 12 months, Creo and Intuitive will carefully roll out a
controlled clinical pioneer programme across multiple sites in the UK and
Europe under which a number of trained Ion users will learn how to
simultaneously use Creo's MicroBlate Flex device for microwave ablation of
cancerous tissue. The first cases from these additional sites are expected to
begin before the end of the calendar year, alongside the continuation of the
work being undertaken at the Royal Brompton.

 

As is typical in such a controlled market release, the CROMA system will be
loaned at no cost along with the MicroBlate Flex devices to cover the initial
cases during the proctoring/mentoring phase before each site enters a
commercial phase. A member of the Intuitive or Creo clinical team will be
present during procedures as part of an oversight program, to carefully
monitor cases during this initial phase.

 

Craig Gulliford, Chief Executive Officer of Creo, said: "This is an exciting
step for all involved as we are already seeing patients for whom this product
is ideally suited. The ability to diagnose and treat an early lesion as part
of a singular anaesthetic event is what we are aiming for and the potential is
clear.

 

"Our mission is to help drive improvements in the survivability of lung cancer
through a combination of precise, accurate diagnosis aligned with precise and
accurately targeted therapy through our Kamaptive partnership programme.

 

"This is an exciting time for the programme for all involved and we look
forward to carefully introducing this to the treatment of an increasing number
of patients in the near future."

 

(1) Bronchoscopic Microwave Ablation of Lung Tissue - Full Text View -
ClinicalTrials.gov
(https://urldefense.proofpoint.com/v2/url?u=https-3A__clinicaltrials.gov_ct2_show_NCT05786625&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=WovxkIrimZbJDsUY12yOjDzcN9uTu1TmGAhgw0TiZCY&m=OyslDpKJqy5cCdxpsKvu7ObhyVN8HFcoqPf4POVajZw&s=Nhy0JhSAmWouYJ4rmkuq8b9i6Y0LIMMiSO07LToAjiw&e=)

(2) https://guysandstthomasspecialistcare.co.uk/news/ion-robot-lung-tumour/
(https://guysandstthomasspecialistcare.co.uk/news/ion-robot-lung-tumour/)

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Richard Craven (Company Secretary)

 Cavendish Capital Markets Limited                  +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR                                        Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                           Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUPUMAMUPCGBG